Compounds

A compound of formula (I):

• wherein:
• R1 is 4-pyridyl which is optionally substituted with one or two substituents each of which is independently selected from C1-4 alkyl, halo, C1-4 alkoxy, C1-4 alkylthio, NH2, mono- or di-C1-6-alkylamino or N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR22;
• R2 is hydrogen, C1-10 alkyl N3, —(CR10R20)nOR12, a heterocyclyl selected from pyrrolidine, piperidine, piperazine, morpholine, imidazolidine or pyrazolidine;
• a heterocyclyl C1-10 alkyl selected from pyrrolidine C1-10 alkyl, piperidine C1-10 alkyl, piperazine C1-10 alkyl, morpholine C1-10 alkyl, imidazolidine C1-10 alkyl, pyrazolidine C1-10 alkyl;
• C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl alkyl, C5-7 cycloalkenyl, aryl, aryl C1-10 alkyl, a heteroaryl selected from pyrrole, quinoline, isoquinoline, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole;
• a heteroaryl C1-10 alkyl selected from pyrrole C1-10 alkyl, quinoline C1-10 alkyl, isoquinoline C1-10 alkyl, pyridine C1-10 alkyl, pyrimidine C1-10 alkyl, oxazole C1-10 alkyl, thiazole C1-10 alkyl, thiadiazole C1-10 alkyl, triazole C1-10 alkyl, imidazole C1-10 alkyl, or benzimidazole C1-10 alkyl;
• (CR10R20)n′OR13, (CR10R20)n′S(O)mR25, (CR10R20)n′NHS(O)2R25, (CR10R20)n′NR8R9, (CR10R20)n′NO2, (CR10R20)n′CN, (CR10R20)n′SO2R25, (CR10R20)n′S(O)mNR8R9, (CR10R20)n′C(Z)R13, (CR10R20)n′C(Z)OR13, (CR10R20)n′C(Z)NR8R9, (CR10R20)n′C(Z)NR13OR2, (CR10R20)n′NR10C(Z)R13, (CR10R20)n′NR10C(Z)NR8R9, (CR10R20)n′N(OR21)C(Z)NR8R9, (CR10R20)n′N(OR21)C(Z)R13, (CR10R20)n′C(═NOR21)R13, (CR10R20)n′NR10C(═NR27)NR8R9, (CR10R20)n′OC(Z)NR8R9, (CR10R20)n′NR10C(Z)NR8R9, (CR10R20)n′NR10C(Z)OR10, 5-(R25)-1,2,4-oxadizaol-3-yl or 4-(R12)-5-(R18R19)-4,5-dihydro-1,2,4-oxadiazol-3-yl;wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl group may be optionally substituted;
• n′ is an integer having a value of 1 to 10;
• m is 0, or the integer 1 or 2;
• R3 is Q—(Y1)t;
• Q is a pyrrolyl or thienyl group;
• t is an integer of 1 to 3;
• n is 0 or an integer from 1 to 10;
• Y1 is independently selected from hydrogen, C1-5 alkyl, halo-substituted C1-5 alkyl, halogen, or —(CR10R20)nY2;
• Y2 is —OR8, —NO2, —S(O)m′R11, —SR8, —S(O)m′OR8, —S(O)mNR8R9, —NR8R9, —O(CR10R20)nNR8R9, —C(O)R8, —C2R8, —CO2(CR10R20)n′CONR8R9, —ZC(O)R8, —CN, —C(Z)NR8R9, —NR10C(Z)R8, —C(Z)NR8OR9, —NR10C(Z)NR8R9, —NR10S(O)mR11, —N(OR21)C(Z)NR8R9, —N(OR21)C(Z)R8, —C(═NOR21)R8, —NR10C═(NR15)SR11, —NR10C(═NR15)NR8R9, —NR10C(═CR14R24)SR11, —NR10C(═CR14R24)NR8R9, —NR10C(O)C(O)NR8R9, —NR10C(O)C(O)OR10, —C(═NR13)NR8R9, —C(═NOR13)NR8R9, —C(═NR13)ZR11, —OC(Z)NR8R9, —NR10S(O)mCF3, —NR10C(Z)OR10, 5-(R18)-1,2,4-oxadizaol-3-yl or 4(R12)-5-(R18R19)-4,5-dihydro-1,2,4-oxadiazol-3-yl;
• m′ is an integer having a value of 1 or 2;
• R4 is phenyl, naphth-1-yl or naphth-2-yl which is optionally substituted by one or two substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-1-yl or 5-naphth-2-yl substituent, is halo, cyano, —C(Z)NR7R17, —C(Z)OR23, —(CR10R20)m′″COR36, SR5, —SOR5, —OR36, halo-substituted C1-4 alkyl, C1-4 alkyl, —ZC(Z)R36, —NR10C(Z)R23, or —(CR10R20)m′″NR10R20 and which, for other positions of substitution, is halo, cyano, —C(Z)NR16R26, —C(Z)OR8, —(CR10R20)m″COR8, —S(O)mR8, —OR8, halo-substituted —C1-4 alkyl, —C1-4 alkyl, —(CR10R20)m″NR10C(Z)R8, NR10S(O)m′R11, —NR10S(O)m′NR7R17 —ZC(Z)R8 or —(CR10R20)m′NR16R26;
• wherein m′ is 0 to 5 and m′″ is 0 or 1;
• R5 is hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR7R17, excluding the moieties SR5 being —SNR7R17 and —SOR5 being —SOH;
• R6 is C1-4 alkyl, halo-substituted —C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or C3-5 cycloalkyl;
• R7 and R17 is each independently selected from hydrogen or C1-4 alkyl or R7 and R17 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR22;
• R8 is hydrogen, heterocyclyl, heterocyclylalkyl or R11;
• R9 is hydrogen, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylalkyl, a heteroaryl selected from pyrrole, quinoline, isoquinoline, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole;
• a heteroarylalkyl selected from pyrrole C1-6 alkyl, quinoline C1-6 alkyl, isoquinoline C1-6 alkyl, pyridine C1-6 alkyl, pyrimidine C1-6 alkyl, oxazole C1-6 alkyl, thiazole C1-6 alkyl, thiadiazole C1-6 alkyl, triazole C1-6 alkyl, imidazole C1-6 alkyl, or benzimidazole C1-6 alkyl;
• or R8 and R9 may together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR12;
• R10 and R20 is each independently selected from hydrogen or C1-4 alkyl;
• R11 is C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylalkyl, a heteroaryl selected from pyrrole, quinoline, isoquinoline, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole;
• a heteroarylalkyl selected from pyrrole C1-6 alkyl, quinoline C1-6 alkyl, isoquinoline C1-6 alkyl, pyridine C1-6 alkyl, pyrimidine C1-6 alkyl, oxazole C1-6 alkyl, thiazole C1-6 alkyl, thiadiazole C1-6 alkyl, triazole C1-6 alkyl, imidazole C1-6 alkyl, or benzimidazole C1-6 alkyl;
• R12 is hydrogen, —C(Z)R13 or optionally substituted C1-4 alkyl, optionally substituted aryl, optionally substituted aryl C1-4 alkyl, or S(O)2R25;
• R13 is hydrogen, C1-10 alkyl, C3-7 cycloalkyl, a heterocyclyl selected from pyrrolidine, piperidine, piperazine, morpholine, imidazolidine or pyrazolidine;
• a heterocyclyl C1-10 alkyl selected from pyrrolidine C1-10 alkyl, piperidine C1-10 alkyl piperazine C1-10 alkyl, morpholine C1-10 alkyl, imidazolidine C1-10 alkyl, or pyrazolidine C1-10 alkylaryl;
• aryl C1-10 alkyl, a heteroaryl selected from pyrrole, quinoline, isoquinoline, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole;
• a heteroaryl C1-10 alkyl selected from pyrrole C1-10 alkyl, quinoline C1-10 alkyl, isoquinoline C1-10 alkyl, pyridine C1-10 alkyl, pyrimidine C1-10 alkyl, oxazole C1-10 alkyl, thiazole C1-10 alkyl, thiadiazole C1-10 alkyl, triazole C1-10 alkyl, imidazole C1-10 alkyl, or benzimidazole C1-10 alkyl;
• R14 and R24 is each independently selected from hydrogen, alkyl, nitro or cyano;
• R15 is hydrogen, cyano, C1-4 alkyl, C3-7 cycloalkyl or aryl;
• R16 and R26 is each independently selected from hydrogen or optionally substituted C1-4 alkyl, optionally substituted aryl or optionally substituted aryl-C1-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR12;
• R18 and R19 is each independently selected from hydrogen, C1-4 alkyl, substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl or together denote a oxygen or sulfur;
• R21 is hydrogen, a pharmaceutically acceptable cation, C1-10 alkyl, C3-7 cycloalkyl, aryl, aryl C1-4 alkyl, a heteroaryl selected from pyrrole, quinoline, isoquinoline, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole;
• a heteroarylalkyl selected from pyrrole C1-6 alkyl, quinoline C1-6 alkyl, isoquinoline C1-6 alkyl, pyridine C1-6 alkyl, pyrimidine C1-6 alkyl, oxazole C1-6 alkyl, thiazole C1-6 alkyl, thiadiazole C1-6 alkyl, triazole C1-6 alkyl, imidazole C1-6 alkyl, or benzimidazole C1-6 alkyl;
• a heterocyclyl selected from pyrrolidine, piperidine, piperazine, morpholine, imidazolidine or pyrazolidine;
• aroyl, or C1-10 alkanoyl;
• R22 is R10 or C(Z)—C1-4 alkyl;
• R23 is C1-4 alkyl, halo-substituted-C1-4 alkyl, or C3-5 cycloalkyl;
• R36 is hydrogen or R23;
• R25 is C1-10 alkyl, C3-7 cycloalkyl, aryl, ary C1 alkyl, a heterocyclyl selected from pyrrolidine, piperidine, piperazine, morpholine, imidazolidine or pyrazolidine;
• a heterocyclyl C1-10 alkyl selected from pyrrolidine C1-10 alkyl, piperidine C1-10 alkyl, piperazine C1-10 alkyl, morpholine C1-10 alkyl, imidazolidine C1-10 alkyl, or pyrazolidine C1-10 alkyl;
• a heteroaryl selected from pyrrole, quinoline, isoquinoline, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole;
• a heteroaryl C1-10 alkyl selected from pyrrole C1-10 alkyl, quinoline C1-10 alkyl, isoquinoline C1-10 alkyl, pyridine C1-10 alkyl, pyrimidine C1-10 alkyl, oxazole C1-10 alkyl, thiazole C1-10 alkyl, thiadiazole C1-10 alkyl, triazole C1-10 alkyl, imidazole C1-10 alkyl, or benzimidazole C1-10 alkyl;
• R27 is hydrogen, cyano, C1-4 alkyl, C3-7 cycloalkyl, or aryl;
• or a pharmaceutically acceptable salt thereof.